Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor ...